Page 2 - Cardiocentro Ticino News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Abbott s XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients

Abbott s XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Marco valgimigliCardiocentro ticinoUniversity of the italian switzerlandItalian switzerlandNick westபல்கலைக்கழகம் ஆஃப் தி இத்தாலிய சுவிட்சர்லாந்துஇத்தாலிய சுவிட்சர்லாந்துநிக் மேற்கு

Abbott s XIENCE Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy for High Bleeding Risk Patients

Abbott today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy as short as 28 days, the shortest indication available in the world for patients with high bleeding risk . The approval follows recent results from two studies that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients and is intended to improve … – Abbott (NYSE: ABT) today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) as short as 28 days, the shortest indication available in the world for patients with high bleeding risk (HBR). The approval follows recent results from two studies that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients and is intended to improve patient outcomes and provide physicians more options to treat their patients. XIENCE is the most widely used stent worldwide and

Marco valgimigliCardiocentro ticinoUniversity of the italian switzerlandItalian switzerlandNick westபல்கலைக்கழகம் ஆஃப் தி இத்தாலிய சுவிட்சர்லாந்துஇத்தாலிய சுவிட்சர்லாந்துநிக் மேற்கு

Gaensel Energy Group, Inc (GEGR) Acquires SSCB Swiss Stem Cells Biotech, the Only Private Stem Cell Biobank in Switzerland

Gaensel Energy Group, Inc. (GEGR) Acquires SSCB Swiss Stem Cells Biotech, the Only Private Stem Cell Biobank in Switzerland Gaensel Energy Group, Inc. https://orders.newsfilecorp.com/files/7475/77566 d11048e994f20a54 001full.jpg Swiss Stem Cells Biotech https://orders.newsfilecorp.com/files/7475/77566 d11048e994f20a54 002full.jpg The Company is pleased to announce the first of at least 2 acquisitions in the Biotech Industry. SSCB is a world renowned participant in Stem Cell Technology and places Gaensel in the front of this exciting and revolutionary health technology. The Board expressed its pleasure working with the President Claudio Massa where he and his advisors have worked tirelessly over the past ninety days to ensure the success of the negotiations and final agreements being completed. The Shareholders of Gaensel will see the long term value this new partnership brings to the Company.

Switzerland generalSalt lake cityUnited statesNuevo leóxNorth carolinaDuke universityClaudio massaKostenloser wertpapierhandelCardiocentro ticinoDevelopment for regenerative medicineSwiss federal office of public healthBiotech companyQuality assurance departmentSwiss institute for therapeutic productsUniversity hospital of monterreyRenewable energy

Site Investigators Missed Clinical Events in GLOBAL LEADERS

February 12, 2021 In an international pragmatic study testing a strategy of shortened dual antiplatelet therapy (DAPT) for patients who receive a drug-eluting stent, nearly one in five clinical outcome events were missed by site investigators, according to an analysis from the GLOBAL LEADERS Adjudication Substudy (GLASSY). Overall, the diagnostic accuracy of clinical events reported by site investigators was modest, while the concordance was generally weak between investigator-reported MIs, strokes, bleeding events, and stent thromboses and those captured by the formal clinical event committee (CEC). “We did see that relying exclusively on investigator-reported events is very suboptimal, as events were reported by investigators which were not confirmed by the central process and, also vice versa, that the central process detected a considerable number of events which were not reported originally by the investigators,” said senior author Marco Valgimigli, MD, PhD (Cardiocent

United kingdomSan franciscoUnited statesCity ofDavid newbyMarco valgimigliSanket dhruvaPoliclinicos matteoCardiocentro ticinoSergio leonardiPhd university of edinburghMd university of paviaMd university of californiaBiosensors internationalUniversity of edinburghNational health service